Increased Serum Zonulin Levels as an Intestinal Permeability Marker in Autistic Subjects

Journal of Pediatrics

Volumn 188, Issue , 2017, Pages 240-244

  Esnafoglu, Erman ^a   Cırrık, Selma ^a   Ayyıldız, Sema Nur ^a   Erdil, Abdullah ^a   Ertürk, Emine Yurdakul ^a   Daglı, Abdullah ^a   Noyan, Tevfik ^a  

^a ORDU UNIVERSITY   (Turkey)

Author keywords

autism spectrum disorder; gastrointestinal system; GI brain interaction; intestinal permeability; tight junctions; zonulin

Indexed keywords

BIOLOGICAL MARKER; TIGHT JUNCTION PROTEIN; UNCLASSIFIED DRUG; ZONULIN; CHOLERA TOXIN;

ARTICLE; AUTISM; BLOATING; CHILD; CHILDHOOD AUTISM RATING SCALE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE CELL; INTESTINE MUCOSA PERMEABILITY; MALE; NAUSEA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RATING SCALE; SCHOOL CHILD; STOMACH PAIN; TIGHT JUNCTION; VOMITING; BLOOD; CASE CONTROL STUDY; INTESTINE; METABOLISM; PERMEABILITY;

AUTISTIC DISORDER; BIOMARKERS; CASE-CONTROL STUDIES; CHILD; CHOLERA TOXIN; FEMALE; HUMANS; INTESTINES; MALE; PERMEABILITY;

EID: 85019110842     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2017.04.004     Document Type: Article

References (43)

1. American Psychiatry Association, Diagnostic and statistical manual of mental disorders. 5th ed, 2013, American Psychiatry Association, Washington (DC).
2. Lai, M.C., Lombardo, M.V., Baron-Cohen, S., Autism. Lancet 383 (2014), 896–910.
3. Mandy, W., Lai, M.C., Annual Research Review: the role of the environment in the developmental psychopathology of autism spectrum condition. J Child Psychol Psychiatry 57 (2016), 271–292.
4. Molloy, C.A., Manning-Courtney, P., Prevalence of chronic gastrointestinal symptoms in children with autism and autistic spectrum disorders. Autism 7 (2003), 165–171.
5. Ibrahim, S.H., Voigt, R.G., Katusic, S.K., Weaver, A.L., Barbaresi, W.J., Incidence of gastrointestinal symptoms in children with autism: a population-based study. Pediatrics 124 (2009), 680–686.
6. Valicenti-McDermott, M., McVicar, K., Rapin, I., Wershil, B.K., Cohen, H., Shinnar, S., Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. J Dev Behav Pediatr 27 (2006), 128–136.
7. Ashwood, P., Anthony, A., Pellicer, A.A., Torrente, F., Walker-Smith, J.A., Wakefield, A.J., Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. J Clin Immunol 23 (2003), 504–517.
8. Galiatsatos, P., Gologan, A., Lamoureux, E., Autistic enterocolitis: fact or fiction?. Can J Gastroenterol 23 (2009), 95–98.
9. Horvath, K., Perman, J.A., Autism and gastrointestinal symptoms. Curr Gastroenterol Rep 4 (2002), 251–258.
10. White, J.F., Intestinal pathophysiology in autism. Exp Biol Med 228 (2003), 639–649.
11. Zioudrou, C., Streaty, R.A., Klee, W.A., Opioid peptides derived from food proteins. The exorphins. J Biol Chem 254 (1979), 2446–2449.
12. Reichelt, K.L., Knivsberg, A.M., Can the pathophysiology of autism be explained by the nature of the discovered urine peptides?. Nutr Neurosci 6 (2003), 19–28.
13. Jyonouchi, H., Geng, L., Ruby, A., Reddy, C., Zimmerman-Bier, B., Evaluation of an association between gastrointestinal symptoms and cytokine production against common dietary proteins in children with autism spectrum disorders. J Pediatr 146 (2005), 605–610.
14. d'Eufemia, P., Celli, M., Finocchiaro, R., Pacifico, L., Viozzi, L., Zaccagnini, M., et al. Abnormal intestinal permeability in children with autism. Acta Paediatr 85 (1996), 1076–1079.
15. de Magistris, L., Familiari, V., Pascotto, A., Sapone, A., Frolli, A., Iardino, P., et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr 51 (2010), 418–424.
16. Kushak, R.I., Buie, T.M., Murray, K.F., Newburg, D.S., Chen, C., Nestoridi, E., et al. Evaluation of intestinal function in children with autism and gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 62 (2016), 687–691.
17. Julio-Pieper, M., Bravo, J.A., Aliaga, E., Gotteland, M., Review article: intestinal barrier dysfunction and central nervous system disorders–a controversial association. Aliment Pharmacol Ther 40 (2014), 1187–1201.
18. Fiorentino, M., Sapone, A., Senger, S., Camhi, S.S., Kadzielski, S.M., Buie, T.M., et al. Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. Mol Autism, 7, 2016, 49.
19. Odenwald, M.A., Turner, J.R., Intestinal permeability defects: is it time to treat?. Clin Gastroenterol Hepatol 11 (2013), 1075–1083.
20. Fasano, A., Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev 91 (2011), 151–175.
21. Fasano, A., Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications. Clin Gastroenterol Hepatol 10 (2012), 1096–1100.
22. Tripathi, A., Lammers, K.M., Goldblum, S., Shea-Donohue, T., Netzel-Arnett, S., Buzza, M.S., et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci U S A 106 (2009), 16799–16804.
23. Sturgeon, C., Fasano, A., Zonulin, a regulator of epithelial and endothelial barrier functions, and its involvement in chronic inflammatory diseases. Tissue Barriers, 4, 2016, e1251384.
24. Zhang, D., Zhang, L., Zheng, Y., Yue, F., Russell, R.D., Zeng, Y., Circulating zonulin levels in newly diagnosed Chinese type 2 diabetes patients. Diabetes Res Clin Pract 106 (2014), 312–318.
25. Jayashree, B., Bibin, Y.S., Prabhu, D., Shanthirani, C.S., Gokulakrishnan, K., Lakshmi, B.S., et al. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol Cell Biochem 388 (2014), 203–210.
26. Sapone, A., De Magistris, L., Pietzak, M., Clemente, M.G., Tripathi, A., Cucca, F., et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 55 (2006), 1443–1449.
27. Żak-Gołąb, A., Kocełak, P., Aptekorz, M., Zientara, M., Juszczyk, Ł., Martirosian, G., et al. Gut microbiota, microinflammation, metabolic profile, and zonulin concentration in obese and normal weight subjects. Int J Endocrinol, 23, 2013, 674106.
28. Moreno-Navarrete, J.M., Sabater, M., Ortega, F., Ricart, W., Fernandez-Real, J.M., Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance. PLoS ONE, 7, 2012 e37160.
29. Sucuoglu, B., Oktem, F., Akkok, F., Gokler, B., A study of the scales for the assessment of the children with autism. J Psychiatry Psychopharmacol Psychol 4 (1996), 116–121 in Turkish.
30. Smecuol, E., Sugai, E., Niveloni, S., Vázquez, H., Pedreira, S., Mazure, R., et al. Permeability, zonulin production, and enteropathy in dermatitis herpetiformis. Clin Gastroenterol Hepatol 3 (2005), 335–341.
31. Reichelt, K.L., Tveiten, D., Knivsberg, A.M., Brønstad, G., Peptides’ role in autism with emphasis on exorphins. Microb Ecol Health Dis, 23, 2012, 10.3402/mehd.v23i0.18958.
32. Ghalichi, F., Ghaemmaghami, J., Malek, A., Ostadrahimi, A., Effect of gluten free diet on gastrointestinal and behavioral indices for children with autism spectrum disorders: a randomized clinical trial. World J Pediatr 12 (2016), 1–7.
33. Buie, T., The relationship of autism and gluten. Clin Ther 35 (2013), 578–583.
34. Whiteley, P., Haracopos, D., Knivsberg, A.M., Reichelt, K.L., Parlar, S., Jacobsen, J., et al. The ScanBrit randomised, controlled, single-blind study of a gluten-and casein-free dietary intervention for children with autism spectrum disorders. Nutr Neurosci 13 (2010), 87–100.
35. Jackson, J.R., Eaton, W.W., Cascella, N.G., Fasano, A., Kelly, D.L., Neurologic and psychiatric manifestations of celiac disease and gluten sensitivity. Psychiatr Q 83 (2012), 91–102.
36. Lionetti, E., Leonardi, S., Franzonello, C., Mancardi, M., Ruggieri, M., Catassi, C., Gluten psychosis: confirmation of a new clinical entity. Nutrients 7 (2015), 5532–5539.
37. Genuis, S.J., Bouchard, T.P., Celiac disease presenting as autism. J Child Neurol 25 (2010), 114–119.
38. Finegold, S.M., State of the art; microbiology in health and disease. Intestinal bacterial flora in autism. Anaerobe 17 (2011), 367–368.
39. de Theije, C.G., Wu, J., da Silva, S.L., Kamphuis, P.J., Garssen, J., Korte, S.M., et al. Pathways underlying the gut-to-brain connection in autism spectrum disorders as future targets for disease management. Eur J Pharmacol 668 (2011), 70–80.
40. Emanuele, E., Orsi, P., Boso, M., Broglia, D., Brondino, N., Barale, F., et al. Low-grade endotoxemia in patients with severe autism. Neurosci Lett 471 (2010), 162–165.
41. Heberling, C.A., Dhurjati, P.S., Sasser, M., Hypothesis for a systems connectivity model of autism spectrum disorder pathogenesis: links to gut bacteria, oxidative stress, and intestinal permeability. Med Hypotheses 80 (2013), 264–270.
42. Leffler, D.A., Kelly, C.P., Abdallah, H.Z., Colatrella, A.M., Harris, L.A., Leon, F., et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol 107 (2012), 1554–1562.
43. Kelly, C.P., Green, P.H.R., Murray, J.A., Dimarino, A., Colatrella, A., Leffler, D.A., et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther 37 (2013), 252–262.